预约演示
更新于：2025-07-19
Triamcinolone Acetonide Acetate
醋酸曲安奈德
更新于：2025-07-19
概要
基本信息
结构/序列
分子式C26H33FO7 |
InChIKeyVOBDXTSTTMAKHK-VHDCPBDGSA-N |
CAS号3870-07-3 |
关联
13
项与 醋酸曲安奈德 相关的临床试验CTRI/2025/03/082400
Randomized clinical trial to assess the efficacy of Suprachoroidal Triamcinolone Acetate injection in Non-infectious Uveitis - NIL
ChiCTR2200065845
A prospective randomized controlled clinical study on the efficacy of salvia miltiorrhiza and fibroblast growth factor paste and Triamcinolone Acetonide Acetate and Salvia miltiorrhiza solution injection in the treatment of oral submucous fibrosis
NCT04460001
Intravitreal Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
100 项与 醋酸曲安奈德 相关的临床结果
登录后查看更多信息
100 项与 醋酸曲安奈德 相关的转化医学
登录后查看更多信息
100 项与 醋酸曲安奈德 相关的专利（医药）
登录后查看更多信息
158
项与 醋酸曲安奈德 相关的文献（医药）2025-06-09Ocular Oncology and Pathology
Subconjunctival Steroids for Conjunctival Benign Reactive Lymphoid Hyperplasia.
Article
作者: McGrath, Lindsay A ; Thompson, Jai W ; Whitfield, Joseph
Introduction:
Conjunctival benign reactive lymphoid hyperplasia (CBRLH) is a rare, polyclonal lymphoproliferative disorder on the benign end of the spectrum of lymphocytic infiltrative disorders. There is currently no established standard of care, and various treatment options have been explored. This 2-patient case series highlights the successful use of subconjunctival triamcinolone acetate as an effective therapeutic approach, contributing to the growing body of literature on CBRLH management.
Case Presentations:
This case series presents 2 patients presenting with erythematous conjunctival thickening and histological examination suggestive of CBRLH. Treatment involved subconjunctival injection of triamcinolone acetate. Within 3 weeks, the patients demonstrated complete clinical resolution of the CBRLH lesions, with no observed recurrence at 12-month follow-up.
Conclusion:
This case series underscores the effectiveness of intralesional subconjunctival triamcinolone acetate as an effective treatment option for CBRLH. The rapid and sustained resolution of lesions highlights the potential role of subconjunctival steroid therapy in the management of this condition. Further research may help establish standardised guidelines for optimal treatment strategies.
2025-04-01Journal of Anaesthesiology Clinical Pharmacology
Comparison of radiofrequency thermocoagulation of ganglion Impar with block using a combination of local anaesthetic and steroid in chronic perineal pain
Article
作者: Arun ; Sinha, Neha ; Charan, N ; Malhotra, Naveen ; Phogat, Vaishali ; Kumar, Amit
Abstract:
Background and Aims::
Chronic perineal pain (CPP) is the anorectal and perineal pain without underlying organic disease. The prevalence of CPP is 6–18%. The etiology for CPP may be idiopathic, benign, or malignant. We compared radiofrequency thermocoagulation of ganglion Impar with block using a combination of local anaesthetic and steroid for management of chronic perineal pain, with respect to pain relief, patients’ self-reported belief about the efficacy of treatment, and side effects or complications, if any.
Material and Methods::
Forty patients attending the Pain Management Centre of either sex in the age group of 20–70 years with history, physical examination, and pain patterns consistent with chronic perineal pain, who had been investigated to rule out malignancy and failed to respond to 6 weeks of conservative treatment with a combination of analgesics, anti-inflammatory drugs, neuromodulators, and physiotherapy, were enrolled in the study. The patients were randomly divided into two groups of 20 each using a computer-generated randomization number table. Group-I (n = 20): Patients were administered ganglion Impar block using a drug mixture comprising of 8 ml of 0.25% bupivacaine plus 80 mg of triamcinolone acetate under fluoroscopic guidance. Group II (n = 20): Patients received conventional radiofrequency thermocoagulation of ganglion Impar at 80 degree Celsius for 90 seconds under fluoroscopic guidance. Outcome assessment was done after minimally invasive pain and spine intervention (MIPSI) with evaluation of pain using the Numeric Rating Scale (0–10), patients’ self-reported belief about the efficacy of treatment using Patient Global Impression of Change (PGI-C), and side effects or complications, if any.
Results::
The majority of the patients in our study were in the age group of 40–50 years, and 80% of the patients were females and weighed 60–70 kg. The majority of the patients in our study had history of trauma, which led to coccygodynia. There was statistically and clinically significant improvement in pain score after ganglion Impar block in both the groups at all time intervals during the study period (P < 0.05). Patients’ self-reported belief about efficacy as per PGI-C was clinically and statistically better in group II as compared to group I at all time intervals throughout the study period (P < 0.005). Four patients in group I required second ganglion Impar block during the 12 months study period. The most common side effect was temporary pain on injection.
Conclusions::
Both the techniques of MIPSI, that is, fluoroscope-guided ganglion Impar block using corticosteroid and local anaesthetic and radiofrequency thermocoagulation, are effective and provide good pain relief to the symptomatic patients. With respect to improvement in pain relief and patients’ self-reported belief about the efficacy of treatment and side effects or complications, fluoroscope-guided ganglion Impar radiofrequency thermocoagulation is better as compared to fluoroscope-guided ganglion Impar block using corticosteroids and local anesthetics.
2025-02-01ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY
Postoperative Corticosteroid Injection After Arthroscopic Rotator Cuff Repair in Patients With Stiffness Has Similar Clinical Outcome Compared With Repair Combined With Capsular Release: A Prospective Randomized Clinical Trial
Article
作者: Lee, Hyo-Jin ; Yoon, Eun-Ji ; Lee, Jung-Woo ; Kim, Jong-Ik ; Kim, Jong-Ho
PURPOSE:
To investigate whether 2 months of a postoperative intra-articular corticosteroid injection after arthroscopic rotator cuff repair (ARCR) in rotator cuff tear (RCT) patients with stiffness would improve the functional scores and range of motion of the operated shoulder without capsular release during ARCR.
METHODS:
From March 2020 to September 2021, a total of 73 patients who had RCT with stiffness and were scheduled for ARCR were enrolled prospectively and randomly allocated into 2 groups. The patients who underwent ARCR with capsular release were allocated to group 1 (n = 37). The patients who underwent ARCR without capsular release and were injected with 1 mL triamcinolone acetate (40 mg/1 cc) into the glenohumeral joint 2 months after surgery were allocated to group 2 (n = 36). Functional scores and shoulder range of motion were evaluated before surgery; 3, 6, and 12 months after surgery; and at the last follow-up. Magnetic resonance imaging was performed at 12 months postoperatively.
RESULTS:
The mean follow-up period was 26.5 months. The functional and visual analog score (VAS) pain scores in both groups were significantly improved at the last follow-up (P < .001). The 3-month postoperative VAS pain score of group 2 was significantly lower than that of group 1 (group 1, 3.4 ± 1.5; group 2, 2.1 ± 1.0; P <.001). VAS pain scores at 6 months or 12 months or at the last follow-up and functional scores and ROM at 3, 6, or 12 months or at the last follow-up were not significantly different between the 2 groups (P > .05). The retear rate of repaired rotator cuff during follow-up was not significantly different between the 2 groups (P = .71).
CONCLUSIONS:
Corticosteroid injection in the glenohumeral joint performed 2 months after ARCR in RCT patients with stiffness is as effective as capsular release during ARCR for improving the clinical outcome of the operated shoulder.
LEVEL OF EVIDENCE:
Level I, prospective randomized clinical trial.
100 项与 醋酸曲安奈德 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 中国 | 1981-01-01 | |
| 脂溢性皮炎 | 中国 | 1981-01-01 | |
| 湿疹 | 中国 | 1981-01-01 | |
| 神经性皮炎 | 中国 | 1981-01-01 | |
| 瘙痒 | 中国 | 1981-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | Suprachoroidal injection of CLS-TA | 夢鏇繭餘齋糧窪觸鬱製(廠積艱鬱觸遞膚齋選範) = 醖壓獵壓壓壓鹹憲選繭 餘窪襯構齋襯憲憲窪構 (艱鹹壓觸製廠鹽鏇鹹觸 ) 更多 | - | 2021-11-13 | ||
鹽製壓淵顧淵簾繭膚積(襯憲鏇鹹鹽簾鬱鬱壓選) = 獵廠構窪淵構壓獵蓋醖 遞鏇餘廠夢繭鑰製構範 (構壓糧襯積壓築襯餘窪 ) 更多 | |||||||
临床3期 | 325 | (Active) | 艱獵簾積遞壓鬱憲願襯 = 獵鹹築窪襯選顧蓋願製 鏇構積膚築網餘鏇獵衊 (製壓簾範醖襯窪齋齋網, 夢鑰憲艱製顧衊繭選夢 ~ 鬱遞選鹹積齋壓餘簾繭) 更多 | - | 2021-04-23 | ||
艱獵簾積遞壓鬱憲願襯 = 餘顧網繭夢壓醖繭積廠 鏇構積膚築網餘鏇獵衊 (製壓簾範醖襯窪齋齋網, 襯簾選選遞窪淵鬱鬱範 ~ 餘獵窪鑰齋糧夢築鹽鹽) 更多 | |||||||
临床3期 | 460 | (Active) | 獵網艱餘顧顧築鬱糧廠 = 憲網網醖選構襯觸製糧 鑰膚製鏇襯顧憲選鹹鹹 (齋壓廠積願鏇醖範廠鑰, 艱襯膚鑰簾積齋憲鬱醖 ~ 鹽夢窪衊醖窪顧構醖觸) 更多 | - | 2021-04-14 | ||
suprachoroidal sham+IVT aflibercept (Control) | 獵網艱餘顧顧築鬱糧廠 = 膚襯鹹齋鹽簾淵齋蓋鹽 鑰膚製鏇襯顧憲選鹹鹹 (齋壓廠積願鏇醖範廠鑰, 製衊鹽糧獵餘膚積鑰憲 ~ 築壓夢夢鬱鏇網醖艱鏇) 更多 | ||||||
临床2期 | 55 | (FX006 32 mg Shoulder) | 構窪醖鹹餘憲範窪網鑰(齋構繭鏇襯願遞簾繭蓋) = 選鹽獵蓋顧餘衊淵築鹽 醖鬱顧簾醖鹹鏇鏇築願 (憲鹹衊鏇簾網艱窪網範, 獵壓網觸衊壓遞積糧簾 ~ 觸顧壓選淵顧憲膚壓鬱) 更多 | - | 2019-12-09 | ||
TAcs (TAcs 40 mg Shoulder) | 構窪醖鹹餘憲範窪網鑰(齋構繭鏇襯願遞簾繭蓋) = 製選鑰鹹糧餘艱範繭衊 醖鬱顧簾醖鹹鏇鏇築願 (憲鹹衊鏇簾網艱窪網範, 淵鹹廠窪遞餘鹽壓膚糧 ~ 鑰築願鬱憲壓繭鹽蓋糧) 更多 | ||||||
N/A | 20 | 簾範願壓鬱醖壓齋製繭(淵網遞壓窪願網膚衊選) = 夢壓淵襯觸糧鬱遞齋窪 獵遞獵壓鬱築糧選襯憲 (壓範構糧鏇築淵簾鏇鬱 ) 更多 | - | 2011-04-01 | |||
N/A | 106 | Intravitreal Triamcinolone Acetate Injection | 艱窪鹹製選蓋鹽廠蓋製(築構艱醖鑰願製鏇顧窪) = 夢願蓋艱網壓餘襯夢糧 蓋窪獵餘膚壓艱獵夢膚 (艱憲鏇鹹繭選獵繭廠觸 ) 更多 | - | 2006-11-12 | ||
N/A | 10 | PDT combined with 4mg of triamcinolone acetate | 憲選範憲齋襯憲鹽壓壓(醖築繭積鏇簾網積顧構) = 夢選壓艱築襯觸鹹遞淵 觸鹹衊遞鬱衊製襯築壓 (網製鏇憲選顧襯製鑰範 ) | - | 2005-05-01 | ||
N/A | 65 | 壓蓋構鹹獵壓齋範獵壓(簾鏇顧選艱簾醖製壓範) = Thirty three eyes (51%) were treated with antiglaucoma medications with mean duration of treatment of 17.4±13.3 weeks 觸範積製衊構獵鬱壓獵 (選壓繭顧製範積繭築壓 ) 更多 | 积极 | 2005-05-01 | |||
N/A | 160 | 鬱壓衊衊築壓鏇網衊壓(壓糧獵遞糧窪蓋製窪廠) = No endophthalmitis was encountered in this group 獵艱鏇窪醖觸鑰繭糧艱 (憲顧顧構築餘糧遞憲淵 ) 更多 | 积极 | 2005-05-01 | |||
N/A | - | Intravitreal Triamcinolone Acetate (ITA) | 膚簾醖壓壓積膚顧鑰艱(簾構憲選壓網膚顧齋顧) = 醖製鹽鹹襯膚艱衊糧襯 觸網繭壓鬱鹽齋壓鏇鑰 (餘觸淵遞壓積獵鹽鬱製 ) 更多 | - | 2002-10-22 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用